Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences operating margin
Operating margin is operating income as a percentage of revenue.
Pacira BioSciences's operating margin for the twelve months ending Jun 30, 2026 was 2.7%. For fiscal 2025 it was 2.6%, against -10.5% the year before. The highest annual figure on record is 16.6% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.6% | +13.1 |
| FY2024 | Dec 31, 2024 | -10.5% | −23.5 |
| FY2023 | Dec 31, 2023 | 13.0% | +4.0 |
| FY2022 | Dec 31, 2022 | 9.0% | −7.6 |
| FY2021 | Dec 31, 2021 | 16.6% | +5.8 |
| FY2020 | Dec 31, 2020 | 10.8% | +8.3 |
| FY2019 | Dec 31, 2019 | 2.5% | −2.2 |
| FY2018 | Dec 31, 2018 | 4.7% | +13.4 |
| FY2017 | Dec 31, 2017 | -8.7% | +2.9 |
| FY2016 | Dec 31, 2016 | -11.6% | −15.4 |
| FY2015 | Dec 31, 2015 | 3.8% | +6.4 |
| FY2014 | Dec 31, 2014 | -2.6% | +59.7 |
| FY2013 | Dec 31, 2013 | -62.3% | +63.8 |
| FY2012 | Dec 31, 2012 | -126.1% | +123.1 |
| FY2011 | Dec 31, 2011 | -249.2% | −93.3 |
| FY2010 | Dec 31, 2010 | -155.9% | +34.3 |
| FY2009 | Dec 31, 2009 | -190.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 2.2% | −2.5 |
| Q1 FY2026 | Mar 31, 2026 | 3.9% | +2.7 |
| Q4 FY2025 | Dec 31, 2025 | 1.2% | −12.0 |
| Q3 FY2025 | Sep 30, 2025 | 3.5% | +86.3 |
| Q2 FY2025 | Jun 30, 2025 | 4.7% | −11.2 |
| Q1 FY2025 | Mar 31, 2025 | 1.2% | −6.7 |
| Q4 FY2024 | Dec 31, 2024 | 13.2% | −5.1 |
| Q3 FY2024 | Sep 30, 2024 | -82.8% | −93.6 |
| Q2 FY2024 | Jun 30, 2024 | 15.9% | −7.7 |
| Q1 FY2024 | Mar 31, 2024 | 7.9% | +9.8 |
| Q4 FY2023 | Dec 31, 2023 | 18.3% | +24.1 |
| Q3 FY2023 | Sep 30, 2023 | 10.8% | −1.9 |
| Q2 FY2023 | Jun 30, 2023 | 23.5% | +5.1 |
| Q1 FY2023 | Mar 31, 2023 | -1.9% | −12.9 |
| Q4 FY2022 | Dec 31, 2022 | -5.8% | −8.4 |
| Q3 FY2022 | Sep 30, 2022 | 12.7% | −11.9 |
| Q2 FY2022 | Jun 30, 2022 | 18.4% | −7.3 |
| Q1 FY2022 | Mar 31, 2022 | 11.0% | −5.3 |
| Q4 FY2021 | Dec 31, 2021 | 2.6% | −11.7 |
| Q3 FY2021 | Sep 30, 2021 | 24.6% | +9.6 |
| Q2 FY2021 | Jun 30, 2021 | 25.7% | +35.2 |
| Q1 FY2021 | Mar 31, 2021 | 16.3% | +0.2 |
| Q4 FY2020 | Dec 31, 2020 | 14.3% | +12.9 |
| Q3 FY2020 | Sep 30, 2020 | 15.0% | +12.7 |
| Q2 FY2020 | Jun 30, 2020 | -9.5% | −14.6 |
| Q1 FY2020 | Mar 31, 2020 | 16.2% | +15.0 |
| Q4 FY2019 | Dec 31, 2019 | 1.4% | −11.5 |
| Q3 FY2019 | Sep 30, 2019 | 2.3% | −2.5 |
| Q2 FY2019 | Jun 30, 2019 | 5.1% | −2.6 |
| Q1 FY2019 | Mar 31, 2019 | 1.2% | +10.5 |
| Q4 FY2018 | Dec 31, 2018 | 12.9% | +2.2 |
| Q3 FY2018 | Sep 30, 2018 | 4.9% | +10.2 |
| Q2 FY2018 | Jun 30, 2018 | 7.8% | +30.0 |
| Q1 FY2018 | Mar 31, 2018 | -9.3% | +11.0 |
| Q4 FY2017 | Dec 31, 2017 | 10.7% | +14.1 |
| Q3 FY2017 | Sep 30, 2017 | -5.3% | +25.2 |
| Q2 FY2017 | Jun 30, 2017 | -22.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -20.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -3.4% | – |
| Q3 FY2016 | Sep 30, 2016 | -30.5% | – |
See a number that looks wrong?